Literature DB >> 19723838

Elafin (SKALP/Trappin-2/proteinase inhibitor-3) is produced by the cervix in pregnancy and cervicovaginal levels are diminished in bacterial vaginosis.

Sarah J Stock1, Leanne Duthie, Tina Tremaine, Andrew A Calder, Rodney W Kelly, Simon C Riley.   

Abstract

OBJECTIVES: To examine cervicovaginal elafin production in pregnancy and determine its relationship in bacterial vaginosis. STUDY
DESIGN: Samples of cervicovaginal secretions were collected from women with uncomplicated singleton pregnancies (n = 112) below 20 weeks gestation. Bacterial flora was assessed using Nugent's criteria, and levels of elafin were measured by enzyme-linked immunosorbent serologic assay (ELISA). Elafin expression in the cervix was also examined by immunohistochemistry. In vitro expression of elafin was examined using cervix and vaginal cell lines.
RESULTS: Elafin is expressed in the cervical glandular epithelium. Elafin was found in all 112 samples of cervicovaginal secretions and levels were diminished in women with bacterial vaginosis (P < .05). Interleukin 1beta (IL-1beta) stimulated elafin expression in cells derived from the endocervix, but not in those derived from the vaginal epithelium.
CONCLUSIONS: Elafin is a component of cervicovaginal secretions in pregnancy, and levels are diminished in bacterial vaginosis. It may be an important component of innate immunity in the lower genital tract.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19723838     DOI: 10.1177/1933719109341998

Source DB:  PubMed          Journal:  Reprod Sci        ISSN: 1933-7191            Impact factor:   3.060


  18 in total

Review 1.  Microbiota restoration: natural and supplemented recovery of human microbial communities.

Authors:  Gregor Reid; Jessica A Younes; Henny C Van der Mei; Gregory B Gloor; Rob Knight; Henk J Busscher
Journal:  Nat Rev Microbiol       Date:  2010-11-29       Impact factor: 60.633

2.  In vitro anti-HIV-1 activity in cervicovaginal secretions from pregnant and nonpregnant women.

Authors:  Brenna L Anderson; Mimi Ghosh; Christina Raker; John Fahey; Yan Song; Dwight J Rouse; Charles R Wira; Susan Cu-Uvin
Journal:  Am J Obstet Gynecol       Date:  2012-04-30       Impact factor: 8.661

3.  Neither vaginal nor buccal administration of 800 μg misoprostol alters mucosal and systemic immune activation or the cervicovaginal microbiome: a pilot study.

Authors:  Spyros A Kalams; Lisa M Rogers; Rita M Smith; Louise Barnett; Katie Crumbo; Shonda Sumner; Naomi Prashad; Kyle Rybczyk; Ginger Milne; Scot E Dowd; Erica Chong; Beverly Winikoff; David M Aronoff
Journal:  Eur J Contracept Reprod Health Care       Date:  2016-09-16       Impact factor: 1.848

Review 4.  Cervical remodeling during pregnancy and parturition.

Authors:  Brenda Timmons; Meredith Akins; Mala Mahendroo
Journal:  Trends Endocrinol Metab       Date:  2010-02-19       Impact factor: 12.015

5.  Molecular definition of vaginal microbiota in East African commercial sex workers.

Authors:  John J Schellenberg; Matthew G Links; Janet E Hill; Tim J Dumonceaux; Joshua Kimani; Walter Jaoko; Charles Wachihi; Jane Njeri Mungai; Geoffrey A Peters; Shaun Tyler; Morag Graham; Alberto Severini; Keith R Fowke; T Blake Ball; Francis A Plummer
Journal:  Appl Environ Microbiol       Date:  2011-04-29       Impact factor: 4.792

Review 6.  Innate immunity in the human female reproductive tract: endocrine regulation of endogenous antimicrobial protection against HIV and other sexually transmitted infections.

Authors:  Charles R Wira; Mickey V Patel; Mimi Ghosh; Lucy Mukura; John V Fahey
Journal:  Am J Reprod Immunol       Date:  2011-03       Impact factor: 3.886

7.  Cross-Sectional Analysis of Selected Genital Tract Immunological Markers and Molecular Vaginal Microbiota in Sub-Saharan African Women, with Relevance to HIV Risk and Prevention.

Authors:  Jordan K Kyongo; Tania Crucitti; Joris Menten; Liselotte Hardy; Piet Cools; Johan Michiels; Sinead Delany-Moretlwe; Mary Mwaura; Gilles Ndayisaba; Sarah Joseph; Raina Fichorova; Janneke van de Wijgert; Guido Vanham; Kevin K Ariën; Vicky Jespers
Journal:  Clin Vaccine Immunol       Date:  2015-03-11

8.  Pregnancy-induced changes in immune protection of the genital tract: defining normal.

Authors:  Brenna L Anderson; Hector Mendez-Figueroa; Joshua D Dahlke; Christina Raker; Sharon L Hillier; Susan Cu-Uvin
Journal:  Am J Obstet Gynecol       Date:  2013-01-10       Impact factor: 8.661

9.  Glucocorticoid-induced reversal of interleukin-1β-stimulated inflammatory gene expression in human oviductal cells.

Authors:  Stéphanie Backman; Alexandra Kollara; Robin Haw; Lincoln Stein; Theodore J Brown
Journal:  PLoS One       Date:  2014-05-21       Impact factor: 3.240

10.  Human cathelicidin production by the cervix.

Authors:  Lorraine Frew; Sofia Makieva; Andrew T M McKinlay; Brian J McHugh; Ann Doust; Jane E Norman; Donald J Davidson; Sarah J Stock
Journal:  PLoS One       Date:  2014-08-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.